Prediction of ischemic stroke outcome during thrombolytic therapy

Abstract

The problem of ischemic stroke in the Russian Federation occupies a leading place in the structure of causes of mortality. Among all treatment methods, the systemic thrombolytic therapy with a recombinant tissue plasminogen activator is regarded as the most effective one.
 This review focuses on clinical studies of the safety and effectiveness of this type of treatment, as well as on prognostically unfavorable factors inducing the hemorrhagic transformation of ischemic stroke.